Sarah Hardy

Sarah Hardy is Chief Investment Officer at Archangel Informal Investment Ltd.
Sarah Hardy joined the Technology Transfer team in 2006.
Her role is to identify and cultivate early-stage funding opportunities and project manage a portfolio of healthcare projects.
Her role also involves contract negotiations, due diligence, monitoring patent prosecution and translation strategies leading to commercial exits.
Previously, she had responsibilities to the Physiology and Pharmacology Funding Committee and the Neuroscience and Mental Health Funding Committee, both at the Wellcome Trust.
Prior to joining the Trust, she worked at Parke-Davis Neuroscience Research Centre, Cambridge.
Sarah Hardy has a PhD in Molecular Neuropharmacology from the University of Aberdeen.